The agency reviewed data from the MARIPOSA-2 trial and approved the regimen for patients with common EGFR mutations who are progressing on EGFR inhibitors.
A group of hospital systems are using the machine-learning model to guide decisions on who should be tested for high levels of lipoprotein(a).
If it can secure the funds, Oncolytics will advance the agent into a pivotal study, based on positive data from the Phase I BRACELET-1 trial.